Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• NCCN Guidelines now recommend comprehensive molecular profiling for nonsquamous Non-Small Cell Lung Cancer (NSCLC).
• First-line treatment for EGFR mutation-positive NSCLC includes gefitinib, erlotinib, and afatinib.
• Disease progression is common even with initial treatment response.

Purpose of the Study:

• To outline current recommendations for molecular profiling in NSCLC.
• To describe first-line TKI therapies for EGFR-mutated NSCLC.
• To detail management strategies based on patterns of disease progression.

Main Methods:

• Review of NCCN Guidelines for NSCLC.
• Summary of current first-line TKI treatments for EGFR-positive NSCLC.
• Analysis of treatment approaches for different progression scenarios (systemic, oligoprogression, CNS progression).

Main Results:

• Broad molecular profiling is recommended for all nonsquamous NSCLC patients.
• Gefitinib, erlotinib, and afatinib are recommended first-line TKIs for EGFR-mutated NSCLC.
• Management of progression varies: systemic progression requires TKI switch, while oligoprogression or CNS progression may allow continued TKI with local treatment.

Conclusions:

• Tailoring treatment based on molecular profiling and progression patterns is crucial for NSCLC management.
• Emerging third-generation TKIs and combination therapies (e.g., with VEGFR inhibitors) show promise for improved outcomes.